Vollmuth P, Karschnia P, Sahm F, Park Y, Ahn S, Jain R
Korean J Radiol. 2025; 26(3):246-268.
PMID: 39999966
PMC: 11865903.
DOI: 10.3348/kjr.2024.0982.
Mair M, Leibetseder A, Heller G, Tomasich E, Muller L, Busse I
J Neurol. 2025; 272(3):210.
PMID: 39954095
PMC: 11829921.
DOI: 10.1007/s00415-025-12923-6.
Diaz M, Pan P
Cancer J. 2025; 31(1).
PMID: 39841424
PMC: 11801446.
DOI: 10.1097/PPO.0000000000000760.
Lee M, Karschnia P, Park Y, Choi K, Han K, Choi S
J Neurooncol. 2024; 169(3):531-541.
PMID: 39115615
DOI: 10.1007/s11060-024-04737-9.
Griessmair M, Delbridge C, Ziegenfeuter J, Jung K, Mueller T, Schramm S
Neurooncol Adv. 2024; 6(1):vdae106.
PMID: 39114182
PMC: 11304596.
DOI: 10.1093/noajnl/vdae106.
Diffuse, IDH-wildtype gliomas in adults with minimal histological change and isolated TERT promoter mutation: not simply CNS WHO grade 4.
Priesterbach-Ackley L, Cordier F, de Witt Hamer P, Snijders T, Robe P, Kusters B
Acta Neuropathol. 2024; 148(1):12.
PMID: 39073427
PMC: 11286727.
DOI: 10.1007/s00401-024-02773-3.
Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma.
Fares J, Wan Y, Mair R, Price S
Brain Commun. 2024; 6(2):fcae108.
PMID: 38646145
PMC: 11032202.
DOI: 10.1093/braincomms/fcae108.
Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N, Krenzlin H, Kalasauskas D, Freyschlag C, Schnell O, Misch M
J Neurooncol. 2024; 167(1):133-144.
PMID: 38326661
PMC: 10978634.
DOI: 10.1007/s11060-024-04585-7.
Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.
van Opijnen M, Broekman M, Cuppen E, Dubbink H, Ter Elst A, van Eijk R
J Neurooncol. 2024; 166(3):485-492.
PMID: 38285243
PMC: 10876806.
DOI: 10.1007/s11060-024-04568-8.
Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas.
Liang Q, Jing H, Shao Y, Wang Y, Zhang H
Clin Neuroradiol. 2024; 34(1):33-43.
PMID: 38277059
DOI: 10.1007/s00062-023-01375-y.
Multimodal MRI-based radiomic nomogram for predicting telomerase reverse transcriptase promoter mutation in IDH-wildtype histological lower-grade gliomas.
Huo X, Wang Y, Ma S, Zhu S, Wang K, Ji Q
Medicine (Baltimore). 2023; 102(51):e36581.
PMID: 38134061
PMC: 10735121.
DOI: 10.1097/MD.0000000000036581.
TERTmonitor-qPCR Detection of Mutations in Glioma.
Bras J, Jesus T, Prazeres H, Lima J, Soares P, Vinagre J
Genes (Basel). 2023; 14(9).
PMID: 37761833
PMC: 10530400.
DOI: 10.3390/genes14091693.
Magnetic resonance spectroscopic correlates of progression free and overall survival in "glioblastoma, IDH-wildtype, WHO grade-4".
Sacli-Bilmez B, Danyeli A, Yakicier M, Aras F, Pamir M, Ozduman K
Front Neurosci. 2023; 17:1149292.
PMID: 37457011
PMC: 10339315.
DOI: 10.3389/fnins.2023.1149292.
IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis.
Nakasu S, Deguchi S, Nakasu Y
Brain Tumor Pathol. 2023; 40(3):143-157.
PMID: 37212969
DOI: 10.1007/s10014-023-00463-8.
Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
Kibe Y, Motomura K, Ohka F, Aoki K, Shimizu H, Yamaguchi J
Sci Rep. 2023; 13(1):23.
PMID: 36646712
PMC: 9842655.
DOI: 10.1038/s41598-022-25928-2.
Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5.
Ahmad Z, Rahim S, Abdul-Ghafar J, Chundriger Q, Ud Din N
Int J Gen Med. 2023; 16:107-127.
PMID: 36644568
PMC: 9833325.
DOI: 10.2147/IJGM.S394872.
Weighted correlation network analysis identifies multiple susceptibility loci for low-grade glioma.
Niu X, Pan Q, Zhang Q, Wang X, Liu Y, Li Y
Cancer Med. 2022; 12(5):6379-6387.
PMID: 36305248
PMC: 10028094.
DOI: 10.1002/cam4.5368.
GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer.
McKinney A, Mathur R, Stevers N, Molinaro A, Chang S, Phillips J
Cell Rep. 2022; 40(12):111344.
PMID: 36130485
PMC: 9534059.
DOI: 10.1016/j.celrep.2022.111344.
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
van Opijnen M, Tesileanu C, Dirven L, van der Meer P, Wijnenga M, Vincent A
Neuro Oncol. 2022; 25(4):701-709.
PMID: 35972438
PMC: 10076940.
DOI: 10.1093/neuonc/noac197.
Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status.
Park Y, Kim S, Park C, Ahn S, Han K, Kang S
Eur Radiol. 2022; 32(12):8089-8098.
PMID: 35763095
DOI: 10.1007/s00330-022-08941-x.